Evidence map›Paper›PMID 40353814›Full record

ReviewJournal of medicinal chemistry2025

Stepping Up Medicinal Chemistry Capabilities in Sub-Saharan Africa: Perspectives from Early Career African Drug Discovery Researchers.

Godfrey Mayoka, Peter Mubanga Cheuka

Abstract readReview
In one paragraph

Review in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Godfrey MayokaHelmholtz Institute for Pharmaceutical Research, Helmholtz Centre for Infection Research, 66123 Saarbrucken, Germany.ORCID 0000-0003-2238-1249
Peter Mubanga CheukaDepartment of Pure and Applied Chemistry, School of Natural and Applied Sciences, University of Zambia, 32379 Lusaka, Zambia.ORCID 0000-0001-8594-2467

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite Africa's progress in basic and clinical sciences, gaps persist in its translational capacities, especially medicinal chemistry, a cornerstone of early stage drug discovery. Drawing on experiences as early career researchers and alumni of Africa's premier holistic drug discovery and development center (H3D), this perspective highlights key successes, challenges, and opportunities in Africa. Major barriers to drug discovery in Africa include limited hit-to-lead and lead optimization programs, insufficient Africa-tailored funding, and educational curricula misaligned with real-world drug discovery. We advocate scaling successful models, integrating drug discovery concepts into educational curricula, and forming strategic partnerships with leading African and international institutions. Africa's progress in drug discovery requires innovative funding mechanisms and resource-sharing frameworks adapted to its unique challenges. Targeted investments, collaborative networks, and reciprocal knowledge exchange are essential for Africa to transition from a consumer of global medical innovations to a leading contributor, addressing local healthcare needs and advancing global health equity.

Indexed as

Chemistry, PharmaceuticalDrug DiscoveryResearch PersonnelAfrica South of the SaharaHumans

Identifiers

PMID40353814
PMCPMC12105032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.